A cost of illness study of allergic rhinitis in the United States

Malone, Daniel C.; Lawson, Kenneth A.; Smith, David H.; Arrighi, H. Michael; Battista, Carmelina

doi:10.1016/s0091-6749(97)70296-3

Cited by 173 publications

(160 citation statements)

References 3 publications

Supporting

Mentioning

148

Contrasting

Unclassified

Order By: Relevance

“…The objective of this interview is to determine the individual's ability to cope with the psychological requirements of the military, and in 7 The ICD8 codes for these are 250, 300, 301, 303-304, 345, 346, 493, 507, and 728. 8 See, for example, Ng et al (2001), Ettner et al (1997), Ettner et al (2011), Famulari (1992, Ferrari (1998), Krahn et al (1996), Malone et al (1997), Fanning (1981, and Currie et al (2010). particular this implies an assessment of personal characteristics such as willingness to assume responsibility, independence, outgoing character, persistence, emotional stability and power of initiative (Lindqvist and Vestman 2011).…”

Section: A Data Descriptionmentioning

confidence: 99%

Adolescent health and adult labor market outcomes

Lundborg

Nilsson

Rooth

2014

Journal of Health Economics

View full text Add to dashboard Cite

Whereas a large literature has shown the importance of early life health for adult socioeconomic outcomes, there is little evidence on the importance of adolescent health.We contribute to the literature by studying the impact of adolescent health status on adult labor market outcomes using a unique and large-scale dataset covering almost the entire population of Swedish males. We show that most types of major conditions have long-run effects on future outcomes, and that the strongest effects result from mental conditions. Including sibling fixed effects or twin pair fixed effects reduces the magnitudes of the estimates but they remain substantial.Lundborg: Lund University (address:

show abstract

Section: A Data Descriptionmentioning

confidence: 99%

Adolescent health and adult labor market outcomes

Lundborg

Nilsson

Rooth

2014

Journal of Health Economics

View full text Add to dashboard Cite

show abstract

“…Data indicate that almost a million school days are missed per year as a direct result of allergic rhinitis in the United States. 4 In addition, children with untreated allergy symptoms exhibit lower learning ability at school compared with nonallergic children. 5 Furthermore, if left untreated, allergic rhinitis can potentially exacerbate and contribute to asthma 6 as well as other comorbidities such as conjunctivitis, otitis, dental malocclusions, sinusitis, respiratory infections, and learning problems.…”

mentioning

confidence: 99%

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis

Wahn¹,

Meltzer²,

Finn³

et al. 2003

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Background: This is the first prospective, randomized, doubleblind, placebo-controlled study showing statistical improvement of an H 1 -antihistamine in children with seasonal allergic rhinitis in all symptoms throughout the entire treatment period. Objective: This randomized, placebo-controlled, parallelgroup, double-blind study was performed to assess the efficacy and safety of fexofenadine in children with seasonal allergic rhinitis. Methods: This study was conducted at 148 centers in 15 countries. Nine hundred thirty-five children (aged 6-11 years) were randomized and treated with either fexofenadine HCl 30 mg (n = 464) or placebo (n = 471) tablets twice a day for 14 days. Individual symptoms (sneezing; rhinorrhea; itchy nose, mouth, throat, and/or ears; itchy, watery, and/or red eyes; and nasal congestion) were assessed at baseline and then daily at 7:00 AM and 7:00 PM (±1 hour) during the double-blind treatment period. Each total symptom score was the sum of all symptoms, excluding nasal congestion. The primary efficacy variable was the change from baseline in the average of the daily 12-hour evening reflective total symptom scores throughout the double-blind treatment. Safety was evaluated from adverse-event reporting, vital signs, physical examinations, and clinical laboratory data at screening and study end point.Results: Fexofenadine was significantly superior to placebo in the primary efficacy analysis (P ≤ .0001). Individual symptom scores showed statistically significant superiority compared with placebo (P < .05), including nasal congestion in the evening reflective assessment (P < .05). There was no significant difference in adverse events between fexofenadine and placebo, either overall or by causality.

show abstract

“…So far, SIT is the only available curative approach (41,63), but its application is restricted with regard to polyzensitized and very young patients. But especially the polysensitzed group of patients require therapy for several months of the year and suffer most from decreased QOL (64,65) and reduced productivity at the school or in the working place (66). Despite optimized treatment regimens, including antihistamines, corticosteroids, or mast cell stabilizers, many patients with SAR still have suboptimal symptom control (67).…”

Section: (4) Anti-ige and Allergic Rhinitismentioning

confidence: 99%